New “Semisynthetic” Anti-Malarial Drug is Unneeded and Sets Dangerous Precedent While Threatening Farmer Livelihoods
By Press Release,
SynBioWatch
| 04. 15. 2013
SynBioWatch Press Release:
For Immediate Release
April 15, 2013
Contact: Lisa Archer, Gopal Dayaneni, or Tina Stevens, , (510) 982-1285, info@SynBioWatch.org
Pharmaceutical giant Sanofi Aventis and Amyris Biotech founder Jay Keasling have announced that they intend to replace the entire world supply of the World Health Organization’s preferred anti-malarial treatment derived from botanical artemisinin with a semisynthetic product which employs synthetic biology, a controversial, unregulated biotechnology.
Speaking at a conference in Cambridge, UK, Keasling said, “Moves are afoot to replace the entire world supply” of artemisinin, which is currently produced by thousands of farmers in Kenya, Tanzania, Madagascar, Mozambique, India, Vietnam and China who cultivate sweet wormwood, the natural source of artemisinin. The statement was confirmed in a release by Sanofi outlining their plan to begin large-scale production.
Currently unregulated, synthetic biology is an extreme form of genetic engineering that involves replacing the genetic material of microbes with entirely artificial human designed gene sequences, resulting in new organisms that are then ‘put to work’ as microbial ‘factories.’
The news raised a host of red flags among civil society organizations concerned...
Related Articles
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Darren Incorvaia, Fierce Biotech | 05.28.2025
An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), extending a moratorium that was first proposed in the fallout of a Chinese researcher’s widely decried use of...
Last week, May 21–23, a broad range of experts gathered in Boston to discuss the future of powerful biotechnologies with the potential to change what it means to be human. The fourth in a series of international Summits on human genome editing, this event was organized by the Global Observatory for Genome Editing, which “seeks to expand the range of questions arising at the frontiers of emerging biotechnologies … and fosters international, interdisciplinary, and cross-sectoral dialogue.” Like previous Summits...
By Hannah Devlin, The Guardian | 05.23.2025
The sperm of a man carrying a rare cancer-causing mutation was used to conceive at least 67 children, 10 of whom have since been diagnosed with cancer, in a case that has highlighted concerns about the lack of internationally agreed...
